Stay at the forefront of exosome science. Explore our latest publications, research updates, and industry perspectives from the Yanhua Bio scientific team.
Our scientific team publishes in leading journals, advancing the collective understanding of exosome biology and therapeutic applications.
Zhang Y, Li W, Chen X, et al. Demonstrating 50-fold yield improvement with maintained particle quality and biological activity across 12 cell line sources.
Wang H, Liu J, Zhang Y, et al. Novel targeting strategy achieving 25x tumor enrichment with deep parenchymal penetration confirmed by multiphoton imaging.
Chen L, Zhang Y, Zhao M, et al. Comprehensive characterization of fibroblast reprogramming through miR-29 family delivery via MSC-derived exosomes.
Li W, Zhang Y, et al. Establishing 47-point QC protocol validated across 9 manufacturing sites with less than 10% batch-to-batch variability.
First-in-class exosome therapeutic for tumor microenvironment modulation enters Phase I preparation, marking a major milestone for our oncology pipeline.
New 5,000 sqm cleanroom facility with 12 independent production lines achieves GMP certification, tripling our manufacturing capacity for clinical supply.
Three new Class-A tertiary hospitals join our clinical research network, expanding multi-center trial capabilities across northern and western China.
Explore joint research opportunities with our team.